The clinical data were as follows.
In FSWs, the prevalence of gonorrhoea was 20% (range: 5 to 45) and the prevalence of chlamydia was 32% (range: 8 to 38).
The rate of chlamydia co-infection among FSWs with gonorrhoea was 30% (range: 0 to 100).
The medical care self-seeking rate in FSWs was 50% (range: 0 to 100).
The odds ratio for outreach service acceptance rate compared with medical care self-seeking rate in FSWs was 1.43 (range: 1 to 2).
The follow-up period for primary infections was 30 days.
The infectivity period for secondary infections was 60 days (range: 30 to 90).
The proportion of contacts protected by condoms was 70% (range: 0 to 100).
The odds ratio of percentage of condom use after counselling was 1.3 (range: 1 to 1.5).
The number of male clients per day was 2 (range: 0.5 to 15).
The effectiveness of antimicrobial therapy was 99% (range: 72 to 100) in the treatment of gonorrhoea and 95% (range: 63 to 99) in the treatment of chlamydia.
In male clients, the prevalence of gonorrhoea was 2.4% (range: 1.9 to 2.9) and that of chlamydia was 1.4% (range: 1.1 to 1.7).
The sensitivity of conventional culture was 90% (range: 60 to 97) and the specificity was 100%.
The sensitivity of DNA/RNA hybridisation for Chlamydia trachomatis DNA was 97% (range: 78 to 100) and the specificity was 99% (range: 80 to 100).
The probability of female-to-male transmission per unprotected intercourse was 0.25 (range: 0.2 to 0.3) for gonorrhoea and 0.68 (range: 0.54 to 0.82) for chlamydia.
The probability of male-to-female transmission per unprotected intercourse was 0.6 (range: 0.5 to 0.7) for gonorrhoea and 0.70 (range: 0.56 to 0.84) for chlamydia.
The relative risk of transmission with condoms was 0.42 (range: 0.18 to 0.99) for gonorrhoea and chlamydia.